Literature DB >> 11234778

The BACE gene: genomic structure and candidate gene study in late-onset Alzheimer's disease.

T Murphy1, A Yip, C Brayne, D Easton, J G Evans, J Xuereb, N Cairns, M M Esiri, D C Rubinsztein.   

Abstract

Alzheimer's disease (AD) pathology is characterized by beta-amyloid plaques and neurofibrillary tangles. Studies of autosomal dominant early-onset AD mutations suggest that beta-amyloid overproduction is sufficient to cause AD. Recently, the BACE gene, which encodes beta-secretase, the rate limiting enzyme in beta-amyloid formation, has been identified. Since this gene is a strong candidate gene for late-onset AD because of its function, we have characterized its genomic organization and identified two polymorphisms. Neither of these polymorphisms were associated with AD risk in genetic association studies comparing autopsy-confirmed late-onset AD cases and age-matched non-demented controls. Thus, we find no evidence that this locus influences risk for late-onset AD.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11234778     DOI: 10.1097/00001756-200103050-00040

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  10 in total

1.  BACE1 gene promoter single-nucleotide polymorphisms in Alzheimer's disease.

Authors:  Weihui Zhou; Fang Cai; Yu Li; George S Yang; Kathleen D O'Connor; Robert A Holt; Weihong Song
Journal:  J Mol Neurosci       Date:  2010-05-09       Impact factor: 3.444

2.  Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients.

Authors:  Rena Li; Kristina Lindholm; Li-Bang Yang; Xu Yue; Martin Citron; Riqiang Yan; Thomas Beach; Lucia Sue; Marwan Sabbagh; Huaibin Cai; Philip Wong; Donald Price; Yong Shen
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-20       Impact factor: 11.205

Review 3.  The beta-secretase, BACE: a prime drug target for Alzheimer's disease.

Authors:  R Vassar
Journal:  J Mol Neurosci       Date:  2001-10       Impact factor: 3.444

4.  BACE1 polymorphisms do not influence platelet membrane beta-secretase activity or genetic susceptibility for Alzheimer's disease in the Northern Irish population.

Authors:  S Todd; A J McKnight; W W Liu; R Carson; S Heggarty; B McGuinness; G B Irvine; D Craig; A P Passmore; J A Johnston
Journal:  Neuromolecular Med       Date:  2008-06-26       Impact factor: 3.843

5.  Genetic association of BACE1 gene polymorphism C786G with late-onset Alzheimer's disease in Chinese.

Authors:  Rui Kan; Binbin Wang; Chuanfang Zhang; Feng Jin; Ze Yang; Shun Ji; Zeping Lu; Chenguang Zheng; Li Wang
Journal:  J Mol Neurosci       Date:  2005       Impact factor: 3.444

6.  BACE1 gene variants do not influence BACE1 activity, levels of APP or Aβ isoforms in CSF in Alzheimer's disease.

Authors:  Annica Sjölander; Henrik Zetterberg; Ulf Andreasson; Lennart Minthon; Kaj Blennow
Journal:  Mol Neurodegener       Date:  2010-09-17       Impact factor: 14.195

Review 7.  BACE1: the beta-secretase enzyme in Alzheimer's disease.

Authors:  Robert Vassar
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

8.  The association of three BACE1 gene polymorphisms (exon5 C/G, intron 5 T/G and 3'UTR T/A) with sporadic Alzheimer's disease susceptibility: a meta-analysis.

Authors:  Hai Yuan; Kang Ling; Xunping Du; Pingping Ge; Shaowei Wu; Xiaotong Wang
Journal:  Int J Clin Exp Med       Date:  2015-08-15

9.  Association of G/C (rs638405) Polymorphism in β-secretase Gene with Alzheimer's Disease.

Authors:  Mostafa Chashmpoosh; Hossein Babaahmadi; Rouhollah Mousavidehmordi; Bita Shalbafan; Asma Mohammadi; Alireza Kheirollah
Journal:  Avicenna J Med Biotechnol       Date:  2018 Oct-Dec

10.  The Basic Biology of BACE1: A Key Therapeutic Target for Alzheimer's Disease.

Authors:  S L Cole; R Vassar
Journal:  Curr Genomics       Date:  2007-12       Impact factor: 2.236

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.